293 related articles for article (PubMed ID: 26994345)
21. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
[TBL] [Abstract][Full Text] [Related]
22. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK
Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512
[TBL] [Abstract][Full Text] [Related]
23. Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.
Tariq M; Zhang J; Liang G; Ding L; He Q; Yang B
J Cell Biochem; 2017 Sep; 118(9):2484-2501. PubMed ID: 28106295
[TBL] [Abstract][Full Text] [Related]
24. Programmable Delivery of Immune Adjuvant to Tumor-Infiltrating Dendritic Cells for Cancer Immunotherapy.
Liu J; Li HJ; Luo YL; Chen YF; Fan YN; Du JZ; Wang J
Nano Lett; 2020 Jul; 20(7):4882-4889. PubMed ID: 32551705
[TBL] [Abstract][Full Text] [Related]
25. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
Guiducci C; Vicari AP; Sangaletti S; Trinchieri G; Colombo MP
Cancer Res; 2005 Apr; 65(8):3437-46. PubMed ID: 15833879
[TBL] [Abstract][Full Text] [Related]
26. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.
Georgoudaki AM; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Östling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MC
Cell Rep; 2016 May; 15(9):2000-11. PubMed ID: 27210762
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of let-7b in leukemia associated macrophages inhibit acute myeloid leukemia progression.
Tian C; Li Y; Si J; Kang J; Chen Z; Nuermaimaiti R; Wang Y; Yu Y; Zhao Z; Wang X; Zhang Y; Zhao H; Yang H; You MJ; Zheng G; Wang L
Hematol Oncol; 2023 Aug; 41(3):510-519. PubMed ID: 36579468
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated macrophages and anti-tumor therapies: complex links.
Belgiovine C; D'Incalci M; Allavena P; Frapolli R
Cell Mol Life Sci; 2016 Jul; 73(13):2411-24. PubMed ID: 26956893
[TBL] [Abstract][Full Text] [Related]
29. Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages.
Zhang Y; Chen Y; Li J; Zhu X; Liu Y; Wang X; Wang H; Yao Y; Gao Y; Chen Z
ACS Appl Mater Interfaces; 2021 Jun; 13(21):24442-24452. PubMed ID: 34008947
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
31. Apoptotic Cancer Cells Suppress 5-Lipoxygenase in Tumor-Associated Macrophages.
Ringleb J; Strack E; Angioni C; Geisslinger G; Steinhilber D; Weigert A; Brüne B
J Immunol; 2018 Jan; 200(2):857-868. PubMed ID: 29229677
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatic Analysis and in Vitro Validation of Let-7b and Let-7c in Breast Cancer.
Bozgeyik E
Comput Biol Chem; 2020 Feb; 84():107191. PubMed ID: 31901542
[TBL] [Abstract][Full Text] [Related]
33. Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
Nakahara T; Oba J; Shimomura C; Kido-Nakahara M; Furue M
J Invest Dermatol; 2016 Jan; 136(1):146-53. PubMed ID: 26763434
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10.
Domínguez-Soto A; Sierra-Filardi E; Puig-Kröger A; Pérez-Maceda B; Gómez-Aguado F; Corcuera MT; Sánchez-Mateos P; Corbí AL
J Immunol; 2011 Feb; 186(4):2192-200. PubMed ID: 21239715
[TBL] [Abstract][Full Text] [Related]
35. Exercise, physical activity and breast cancer: the role of tumor-associated macrophages.
Goh J; Kirk EA; Lee SX; Ladiges WC
Exerc Immunol Rev; 2012; 18():158-76. PubMed ID: 22876727
[TBL] [Abstract][Full Text] [Related]
36. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
37. Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.
Baer C; Squadrito ML; Laoui D; Thompson D; Hansen SK; Kiialainen A; Hoves S; Ries CH; Ooi CH; De Palma M
Nat Cell Biol; 2016 Jul; 18(7):790-802. PubMed ID: 27295554
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Proteomics Analysis Reveals Metabolic Reprogramming of Tumor-Associated Macrophages Stimulated by the Tumor Microenvironment.
Liu D; Chang C; Lu N; Wang X; Lu Q; Ren X; Ren P; Zhao D; Wang L; Zhu Y; He F; Tang L
J Proteome Res; 2017 Jan; 16(1):288-297. PubMed ID: 27809537
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype.
Xu M; Liu M; Du X; Li S; Li H; Li X; Li Y; Wang Y; Qin Z; Fu YX; Wang S
J Immunol; 2015 May; 194(10):4997-5006. PubMed ID: 25876763
[TBL] [Abstract][Full Text] [Related]
40. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy.
Liu L; Yi H; He H; Pan H; Cai L; Ma Y
Biomaterials; 2017 Jul; 134():166-179. PubMed ID: 28463694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
